Area of research
Oncology · Immunology
Research interest
Research interests include Immunotherapy and Immune Responses, Monoclonal and Polyclonal Antibodies Research, Cancer Immunotherapy and Biomarkers, and CAR-T cell therapy research.
Therapeutic synthetic and natural materials for immunoengineering
Engineered GM-CSF polarizes protumorigenic tumor-associated macrophages to an antitumorigenic phenotype and potently synergizes with IL-12 immunotherapy
Engineered IL-7 synergizes with IL-12 immunotherapy to prevent T cell exhaustion and promote memory without exacerbating toxicity
Masking the immunotoxicity of interleukin-12 by fusing it with a domain of its receptor via a tumour-protease-cleavable linker
Tumor Cell-Surface Binding of Immune Stimulating Polymeric Glyco-Adjuvant via Cysteine-Reactive Pyridyl Disulfide Promotes Antitumor Immunity
Polymersomes Decorated with the SARS-CoV-2 Spike Protein Receptor-Binding Domain Elicit Robust Humoral and Cellular Immunity
Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant
Immunoengineering approaches for cytokine therapy
Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours
Prolonged residence of an albumin–IL-4 fusion protein in secondary lymphoid organs ameliorates experimental autoimmune encephalomyelitis
Suppression of Rheumatoid Arthritis by Enhanced Lymph Node Trafficking of Engineered Interleukin‐10 in Murine Models
Targeted antibody and cytokine cancer immunotherapies through collagen affinity
Recruitment of CD103 <sup>+</sup> dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy
Engineered collagen-binding serum albumin as a drug conjugate carrier for cancer therapy
Targeting inflammatory sites through collagen affinity enhances the therapeutic efficacy of anti-inflammatory antibodies